ATE254472T1 - Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält - Google Patents

Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält

Info

Publication number
ATE254472T1
ATE254472T1 AT97907445T AT97907445T ATE254472T1 AT E254472 T1 ATE254472 T1 AT E254472T1 AT 97907445 T AT97907445 T AT 97907445T AT 97907445 T AT97907445 T AT 97907445T AT E254472 T1 ATE254472 T1 AT E254472T1
Authority
AT
Austria
Prior art keywords
tfpi
inhibitor
tissue factor
containing tissue
vascular formation
Prior art date
Application number
AT97907445T
Other languages
English (en)
Inventor
Tsutornu Hamuro
Yo Nakahara
Sumiyo Takemoto
Seiji Miyamoto
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE254472T1 publication Critical patent/ATE254472T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97907445T 1996-03-25 1997-03-24 Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält ATE254472T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9617696 1996-03-25
PCT/JP1997/000973 WO1997035609A1 (en) 1996-03-25 1997-03-24 Neovascularization inhibitor containing tissue factor pathway inhibitor

Publications (1)

Publication Number Publication Date
ATE254472T1 true ATE254472T1 (de) 2003-12-15

Family

ID=14158025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907445T ATE254472T1 (de) 1996-03-25 1997-03-24 Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält

Country Status (9)

Country Link
US (1) US6060449A (de)
EP (1) EP0914830B1 (de)
JP (1) JP4129994B2 (de)
KR (1) KR100442758B1 (de)
AT (1) ATE254472T1 (de)
AU (1) AU706582B2 (de)
CA (1) CA2250008A1 (de)
DE (1) DE69726281T2 (de)
WO (1) WO1997035609A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
ATE429643T1 (de) 2000-07-12 2009-05-15 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
IL161407A0 (en) 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2005110059A2 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
EP2338488A1 (de) 2006-05-26 2011-06-29 Bayer HealthCare, LLC Arzneikombinationen mit substituierten Diaryl-Harnstoffen zur Krebsbehandlung
CA2672951A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
US8772238B2 (en) * 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
EP2547355B1 (de) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi-hemmer und verwendungsverfahren dafür
WO2011130728A1 (en) 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
EP2595628A1 (de) 2010-07-19 2013-05-29 Bayer HealthCare LLC Wirkstoffkombinationen mit fluorsubstituiertem omega-carboxyaryl-diphenylharnstoff zur behandlung und prävention von erkrankungen und zuständen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
JP3428687B2 (ja) * 1993-06-30 2003-07-22 財団法人化学及血清療法研究所 組織因子凝固系インヒビターの調製法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation

Also Published As

Publication number Publication date
WO1997035609A1 (en) 1997-10-02
CA2250008A1 (en) 1997-10-02
US6060449A (en) 2000-05-09
KR19990087825A (ko) 1999-12-27
KR100442758B1 (ko) 2004-10-06
EP0914830B1 (de) 2003-11-19
EP0914830A4 (de) 2002-03-20
JP4129994B2 (ja) 2008-08-06
AU1944997A (en) 1997-10-17
DE69726281T2 (de) 2004-08-26
EP0914830A1 (de) 1999-05-12
DE69726281D1 (de) 2003-12-24
AU706582B2 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
SE8503680D0 (sv) Indolderivat
EA199800268A1 (ru) Замещенные имидазолы, обладающие антиканцерогенной и цитокин-ингибирующей активностью
AU3380997A (en) Substituted imidazoles having cytokine inhibitory activity
TNSN94105A1 (fr) Composes sulfonamides tricycliques utiles pour l'inhibition de la fonction proteine g et pour le traitement des maladies proliferatives
DK0950100T3 (da) Keratinocytvækstfaktor-2- (KGF-2- eller fibroblastvækstfaktor-12-, FGF-12-) mutanter
EP0649306A4 (de) Ester derivate von 4-aza-steroiden.
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
FI914723A0 (fi) 17b-substituerade 4-aza-5a-androstan -3-jon-derivat och foerfarande foer framstaellning av desamma.
DE3774918D1 (de) Cancerostatisches mittel.
AU2291097A (en) Novel phenanthridines substituted in the 6 position
DE69726281D1 (de) Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
EP0664128A4 (de) Pharmazeutisches mittel zur hemmung der tumornekrosefaktorproduktion.
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
ATE79031T1 (de) Verwendung von ketonderivaten zur behandlung von depressionen.
DE69720542D1 (de) PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
DE69127976D1 (de) Tropolonderivate und pharmazeutische zubereitungen davon zur vorbeugung und behandlung von ischämischen krankheiten
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
IT1243801B (it) Intermedi per agenti chelanti con simmetria prefissata, e procedimentoper la loro preparazione
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
FR2722689B1 (fr) Nouveau produit de combinaison comprenant un agent antifongique et du crotamiton comme potentialisateur de l'activite de l'agent antifongique, et compositions dermatologiques et/ou cosmetiques le comprenant
TW325472B (en) A pharmaceutical composition for preventing cancer comprising 2-(1-hydroxyethyl)-5-hydroxynaphto[2,3-b]furan-4,9-dione
EA199800033A1 (ru) Антагонисты канала кальция

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties